P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Abstract
The function of p53 as a tumour suppressor has been attributed to its ability to promote cell death or permanently inhibit cell proliferation. However, in recent years, it has become clear that p53 can also contribute to cell survival. p53 regulates various metabolic pathways, helping to balance glycolysis and oxidative phosphorylation, limiting the production of reactive oxygen species, and contributing to the ability of cells to adapt to and survive mild metabolic stresses. Although these activities may be integrated into the tumour suppressive functions of p53, deregulation of some elements of the p53-induced response might also provide tumours with a survival advantage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autophagy is another cellular program that is triggered by cell stress and p53.195, 208”
From Census and evaluation of p53 target genes (2017) · cites this paper as [195]
In the citing paper
“Target genes directly regulated by p53 participate in multiple metabolic pathways.194, 195”
From Census and evaluation of p53 target genes (2017) · cites this paper as [195]
In the citing paper
“Additional signals and persistent stress can lead to sustained expression of p53 and activation of p16INK4A contributing to a long lasting cell cycle arrest (Sharpless and DePinho, 2006; Salama et al., 2014; Kruiswijk et al., 2015).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Kruiswijk et al., 2015
In the citing paper
“Second, most types of cellular stress are able to induce a p53 response, but they all use different mechanisms to activate the protein [65, 66, 67].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [67]
In the citing paper
“p53 also promotes fatty acid oxidation by activating the expression of CPT1C, MCD and PANK1.107”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [107]
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Autophagy: Renovation of Cells and Tissues
Mizushima, N., & Komatsu, M. (2011) · Cell · doi:10.1016/j.cell.2011.10.026 · Cited by 6,418
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Self-citationBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Self-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Cited by
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
“Loss of p53 increases glycolytic flux to promote anabolism and redox balance, two key processes that promote tumorigenesis (19).”
BackgroundTargeting Ferroptosis to Iron Out Cancer
Hassannia, B., Vandenabeele, P., & Vanden Berghe, T. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.002 · Cited by 2,478
ROS signalling in the biology of cancer
Moloney, J. N., & Cotter, T. G. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.05.023 · Cited by 1,970
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
“Additional signals and persistent stress can lead to sustained expression of p53 and activation of p16INK4A contributing to a long lasting cell cycle arrest (Sharpless and DePinho, 2006; Salama et al., 2014; Kruiswijk et al., 2015).”
BackgroundCancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Baar, M. P., Brandt, R. M. C., Putavet, D. A., Klein, J. D. D., Derks, K. W. J., Bourgeois, B. R. M., Stryeck, S., Rijksen, Y., van Willigenburg, H., Feijtel, D. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.031 · Cited by 1,454
“…of nuclei of senescent cells showed FOXO4 to reside within these PML bodies, adjacent to 53BP1-containing DNA-SCARS (Figure 2D; Movies S1 andS2; Figures S2E–S2I). p53 controls both apoptosis and senescence (Kruiswijk et al., 2015) and localizes to DNA-SCARS in senescent cells (Rodier et al., 2011).”
BackgroundSenescence and aging: Causes, consequences, and therapeutic avenues
McHugh, D., & Gil, J. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201708092 · Cited by 1,233
“Although transient increases in p53 levels can enact a quiescent state and activate DNA repair processes, during senescence, there is a sustained induction of p53 (Salama et al., 2014; Kruiswijk et al., 2015).”
BackgroundThe multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Lang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., Liao, P., Zhou, J., Zhang, Q., Dow, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0338 · Cited by 1,047
“Along this line, p53 contributes to tumor-cell survival but also promotes tumor-cell death (35).”
BackgroundThe hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“107 Ammonia is a prevalent product of cellular metabolism.”
BackgroundSerine and one-carbon metabolism in cancer
Yang, M., & Vousden, K. H. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.81 · Cited by 992
Self-citationCensus and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Wang, B., Wang, Y., Zhang, J., Hu, C., Jiang, J., Li, Y., & Peng, Z. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03476-6 · Cited by 858
ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway
Chu, B., Kon, N., Chen, D., Li, T., Liu, T., Jiang, L., Song, S., Tavana, O., & Gu, W. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0305-6 · Cited by 882
Revisiting the hallmarks of cancer.
Fouad, Y. A., & Aanei, C. M. (2017) · Europe PMC (PubMed Central) · Cited by 1,245
Autophagy-Independent Functions of the Autophagy Machinery
Galluzzi, L., & Green, D. R. (2019) · Cell · doi:10.1016/j.cell.2019.05.026 · Cited by 863
“The ultimate metabolic catastrophe promoted by the absence of ATG7 irrespective of bona fide autophagic responses may reflect the ability of p53 to support the maintenance of metabolic homeostasis at baseline (Kruiswijk et al., 2015).”
BackgroundMutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
“help the cell adapt to and survive mild stress conditions, including oxidative and metabolic stress [7].”
The tumor suppressor protein p53 and the ferroptosis network
Kang, R., Kroemer, G., & Tang, D. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.05.074 · Cited by 698
LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer
Tan, Y., Lin, J., Li, T., Li, J., Xu, R., & Ju, H. (2021) · Cancer Communications · doi:10.1002/cac2.12108 · Cited by 700
“[84] proposed that cell metabolism was a noncanonical p53-controlled process, and this idea had attracted”
BackgroundOxidative Stress in Cancer Cell Metabolism
Arfin, S., Jha, N. K., Jha, S. K., Kesari, K. K., Ruokolainen, J., Roychoudhury, S., Rathi, B., & Kumar, D. (2021) · Antioxidants · doi:10.3390/antiox10050642 · Cited by 665
“For instance, p53 could regulate the expression of various antioxidant enzymes including catalase, SOD2, and GPX1 thereby decreasing ROS accumulation [62].”
BackgroundMechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions
Yan, M., Huo, Y., Yin, S., & Hu, H. (2018) · Redox Biology · doi:10.1016/j.redox.2018.04.019 · Cited by 676
The Two Faces of Reactive Oxygen Species in Cancer
Reczek, C. R., & Chandel, N. S. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041916-065808 · Cited by 602
“CAT can very efficiently convert H2O2 to H2O and O2 in the absence of any cofactors in the peroxisomes of most cells.”
BackgroundInfluentialDixon, S. J., & Stockwell, B. R. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055844 · Cited by 577
“While unsatisfying, this interpretation would be consistent with the ability of p53 to influence other biological processes within the cell in both a positive and negative manner, depending on the situation (Kruiswijk et al. 2015).”
BackgroundTissue of origin dictates branched-chain amino acid metabolism in mutant Kras -driven cancers
Mayers, J. R., Torrence, M. E., Danai, L. V., Papagiannakopoulos, T., Davidson, S. M., Bauer, M. R., Lau, A. N., Ji, B. W., Dixit, P. D., Hosios, A. M., et al. (2016) · Science · doi:10.1126/science.aaf5171 · Cited by 582
“TP53 mutations increase glucose consumption and glycolytic flux, while inactivation of TP53 renders cancer cells more dependent on serine uptake and metabolism (6).”
BackgroundChronic and Acute Toxicities of Aflatoxins: Mechanisms of Action
Benkerroum, N. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17020423 · Cited by 554
“part or all of which are involved in tumour suppression, as has been extensively reviewed recently [29,58-59,64,71-73].”
Backgroundp53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells
Tarangelo, A., Magtanong, L., Bieging-Rolett, K. T., Li, Y., Ye, J., Attardi, L. D., & Dixon, S. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.077 · Cited by 554
“Depending on the context, p53 can either promote or prevent cell death (Kruiswijk et al., 2015; Paek et al., 2016).”
The emerging role and targetability of the TCA cycle in cancer metabolism
Anderson, N. M., Mucka, P., Kern, J. G., & Feng, H. (2018) · Protein & Cell · doi:10.1007/s13238-017-0451-1 · Cited by 556
Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Park, J. H., Pyun, W. Y., & Park, H. W. (2020) · Cells · doi:10.3390/cells9102308 · Cited by 548
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 483
Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments
Zuo, L., Prather, E. R., Stetskiv, M., Garrison, D. E., Meade, J. R., Peace, T. I., & Zhou, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184472 · Cited by 539
“However, under oxidative stress, p53 may exhibit pro-oxidant properties [45].”
Backgroundp53 in ferroptosis regulation: The new weapon for the old guardian
Liu, Y., & Gu, W. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00943-y · Cited by 540
“This duality of p53 in ferroptosis regulation is reminiscent of how p53 functions in the DNA damage response, cellular metabolism regulation, or non-ferroptosis redox control [17, 74].”
BackgroundROS in Cancer: The Burning Question
Chio, I. I. C., & Tuveson, D. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.004 · Cited by 532
“…ROS accumulation by directly regulating the expression of a variety of antioxidant genes including SOD2, GPX1 and CAT (Budanov et al., 2004; Kruiswijk et al., 2015), and indirectly through the induction of the metabolic gene TP53-inducible glycolysis and apoptosis regulator (TIGAR)…”
BackgroundUnderstanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Mao, C., Wang, X., Liu, Y., Wang, M., Yan, B., Jiang, Y., Shi, Y., Shen, Y., Liu, X., Lai, W., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3454 · Cited by 494
“For example, p53 can limit the production of ROS and induce apoptosis or ferroptosis (48,49).”
BackgroundMolecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., et al. (2017) · Nature · doi:10.1038/nature24451 · Cited by 463
“Extended Data Table 1 FT671 FT827 USP enzymes USP1/UAF1 103 101 USP2 101 98 USP4 96 93 USP5 115 92 USP5 (1) 112 104 USP5 (2) 110 92 USP6 96 95 USP7 0 14 USP8 94 90 USP9x 93 95 USP11 107 103 USP14 (3) 99 97 USP15 100 104 USP16 96 89 USP19 99 108 USP20 104 115 USP21 100 110 USP25 97 107 USP28 105 108 USP30 103 112 USP35…”
A fate worse than death: apoptosis as an oncogenic process
Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451
From Ancient Pathways to Aging Cells—Connecting Metabolism and Cellular Senescence
Wiley, C. D., & Campisi, J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.010 · Cited by 440
“Beyond establishing the proliferative arrest of senescent cells, p53 also plays an important role in the regulation of glycolysis (Kruiswijk et al., 2015; Puzio-Kuter, 2011).”
Backgroundp53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., & Galluzzi, L. (2020) · Nature Immunology · doi:10.1038/s41590-019-0561-4 · Cited by 385
Modes of Regulated Cell Death in Cancer
Koren, E., & Fuchs, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0789 · Cited by 371
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
“One of the first physiological p53 functions described was its ability to induce apoptosis in transformed cells [55].”
BackgroundLacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
Cancer cell metabolism and antitumour immunity
De Martino, M., Rathmell, J. C., Galluzzi, L., & Vanpouille-Box, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 327
“Indeed, multiple cancer-initiating events, such as activating mutations in KRAS and the genetic or epigenetic inactivation of tumour protein p53 (TP53), have been shown to directly impact catabolism or anabolism 4,5 .”
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 359
Transferrin receptor 1 in cancer: a new sight for cancer therapy.
Shen, Y., Li, X., Dong, D., Zhang, B., Xue, Y., & Shang, P. (2018) · Europe PMC (PubMed Central) · Cited by 483
Santaguida, S., Richardson, A., Iyer, D. R., M'Saad, O., Zasadil, L., Knouse, K. A., Wong, Y. L., Rhind, N., Desai, A., & Amon, A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.05.022 · Cited by 364
“Aneuploidy-associated stresses that include oxidative, metabolic and proteotoxic stress also likely contribute to p53 activation (Kruiswijk et al., 2015), especially in cells with high levels of genomic imbalances such as is seen in aneuploid cells that arrest in G1.”
iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4
Chen, D., Chu, B., Yang, X., Liu, Z., Jin, Y., Kon, N., Rabadan, R., Jiang, X., Stockwell, B. R., & Gu, W. (2021) · Nature Communications · doi:10.1038/s41467-021-23902-6 · Cited by 348
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 353
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Muñoz-Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.99 · Cited by 341
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 328
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
“Besides the mevalonate pathway, several other metabolic processes are impacted by p53 through various mechanisms (Kruiswijk et al., 2015).”
BackgroundMolecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers
Peng, X., Chen, Z., Farshidfar, F., Xu, X., Lorenzi, P. L., Wang, Y., Cheng, F., Tan, L., Mojumdar, K., Du, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.077 · Cited by 341
“For example, mutated TP53 and MYC amplification have been extensively linked to anabolic or catabolic activities, including glycolysis and redox balance in cancer (Kruiswijk et al., 2015; Stine et al., 2015).”
Backgroundp53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
“p53 can also induce a reversible cell cycle arrest, allowing cells to resume proliferation once the damage or stress has been resolved (Agarwal et al., 1995; Kruiswijk et al., 2015; Linke et al., 1996).”
BackgroundSelf-citationMetabolic signatures of cancer cells and stem cells
Intlekofer, A. M., & Finley, L. W. S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0032-0 · Cited by 322
p53 and Tumor Suppression: It Takes a Network
Boutelle, A. M., & Attardi, L. D. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.12.011 · Cited by 317
Mitochondrial ROS control of cancer
Idelchik, M. D. P. S., Begley, U., Begley, T. J., & Melendez, J. A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.005 · Cited by 303
Pan, R., Ruvolo, V., Mu, H., Leverson, J. D., Nichols, G., Reed, J. C., Konopleva, M., & Andreeff, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.003 · Cited by 300
“These observations correspond with previous reports that p53 has lower affinity for BAX and BAK promoters than for MDM2 and BBC3 promoters (Kracikova et al., 2013; Kruiswijk et al., 2015).”
BackgroundTumor suppressor p53 and metabolism
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy070 · Cited by 300
“Tumor suppressor p53 has been reported to play an important role in metabolic regulation in cells (Vousden and Prives, 2009; Liu et al., 2013; Muller and Vousden, 2013; Gurpinar and Vousden, 2015; Kruiswijk et al., 2015).”
Backgroundα-Ketoglutarate links p53 to cell fate during tumour suppression
Morris, J. P., Yashinskie, J. J., Koche, R., Chandwani, R., Tian, S., Chen, C.-C., Baslan, T., Marinkovic, Z. S., Sánchez-Rivera, F. J., Leach, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1577-5 · Cited by 296
Cuproptosis: p53-regulated metabolic cell death?
Xiong, C., Ling, H., Hao, Q., & Zhou, X. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01125-0 · Cited by 263
“Inhibition of glucose uptake or glycolysis may induce a metabolic shift from glycolytic metabolism to mitochondrial metabolism by using alternate energy sources, such as galactose or glutamine, which sensitizes cells to cuproptosis [7, 21].”
BackgroundResultLiao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 261
Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect
Zhang, K., Zhou, Y., Xiao, C., Zhao, W., Wu, H., Tang, J., Li, Z., Yu, S., Li, X., Min, L., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax6946 · Cited by 268
“Second, higher expression of the p53 protein was found in the n-HA group, which responds to cellular stresses to suppress oncogenesis (23).”
BackgroundGut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion
Okumura, S., Konishi, Y., Narukawa, M., Sugiura, Y., Yoshimoto, S., Arai, Y., Sato, S., Yoshida, Y., Tsuji, S., Uemura, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25965-x · Cited by 259
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
Cadmium Exposure: Mechanisms and Pathways of Toxicity and Implications for Human Health
Qu, F., & Zheng, W. (2024) · Toxics · doi:10.3390/toxics12060388 · Cited by 235
“If the damage cannot be repaired, p53 could guide cells towards programmed cell death to prevent the malignant transformation of damaged cells [68].”
BackgroundMutant lamins cause nuclear envelope rupture and DNA damage in skeletal muscle cells
Earle, A. J., Kirby, T. J., Fedorchak, G. R., Isermann, P., Patel, J., Iruvanti, S., Moore, S. A., Bonne, G., Wallrath, L. L., & Lammerding, J. (2020) · Nature Materials · doi:10.1038/s41563-019-0563-5 · Cited by 245
Meitinger, F., Anzola, J. V., Kaulich, M., Richardson, A., Stender, J. D., Benner, C., Glass, C. K., Dowdy, S. F., Desai, A., Shiau, A. K., et al. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201604081 · Cited by 238
“The p53 circuit responds to a myriad of stress signals, including DNA damage, oncogene activation, metabolic fluctuations, and mitotic aberrations, and drives programs that can lead to temporary arrest, senescence, or cell death (Levine and Oren, 2009; Uetake and Sluder, 2010; Ganem et al., 2014; Gurpinar and Vousden,…”
BackgroundInfluentialMutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 235
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3
Tajan, M., Hock, A. K., Blagih, J., Robertson, N. A., Labuschagne, C. F., Kruiswijk, F., Humpton, T. J., Adams, P. D., & Vousden, K. H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.005 · Cited by 230
“Sestrin2, the product of a p53-responsive gene (SESN2), has been shown to help cells adapt to glutamine starvation by promoting FAO (Byun et al., 2017).”
BackgroundSelf-citationDeconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227
“To fuel their enhanced growth and proliferation, neoplastic cells undergo metabolic reprogramming, typically by enhancing glycolytic function and dampening oxidative phosphorylation.(88) Although the role of p53 in metabolism is complex, p53 is thought to oppose this reprogramming.”
BackgroundMetabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
Gandhi, N., & Das, G. (2019) · Cells · doi:10.3390/cells8020089 · Cited by 227
“p53 has been reported to regulate the function of various metabolic pathways at multiple levels [100].”
BackgroundControl of metabolism by p53 – Cancer and beyond
Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 219
Self-citationTranscriptional control of microglia phenotypes in health and disease
Holtman, I. R., Skola, D., & Glass, C. K. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90604 · Cited by 218
“p53 is a well-studied tumor suppressor gene that functions as a complex integrator of signals that regulate DNA damage repair, cell cycle progression, and apoptosis (77).”
BackgroundGanapathy-Kanniappan, S. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1556578 · Cited by 216
“Similarly, tumor suppressors, such as p53 (Bensaad et al. 2006; Kruiswijk et al. 2015) and PTEN (Jang et al. 2013) also affect glycolytic phenotype.”
BackgroundMolecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism
Somasundaram, V., Basudhar, D., Bharadwaj, G., No, J. H., Ridnour, L. A., Cheng, R. Y. S., Fujita, M., Thomas, D. D., Anderson, S. K., McVicar, D. W., et al. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2018.7527 · Cited by 213
“Stabilization of HIF1a induces metabolic genes that are involved in increasing glycolysis, and induction of NFjB increases glucose uptake through induction of the GLUTs (36, 92).”
BackgroundBiological effect of protein modifications by lipid peroxidation products
Gęgotek, A., & Skrzydlewska, E. (2019) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2019.03.011 · Cited by 209
Relevance of the p53–MDM2 axis to aging
Wu, D., & Prives, C. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.187 · Cited by 215
Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy
Wang, S., Fu, J.-L., Hao, H.-F., Jiao, Y.-N., Li, P.-P., & Han, S.-Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105728 · Cited by 200
Deciphering p53 signaling in tumor suppression
Mello, S. S., & Attardi, L. D. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.11.005 · Cited by 206
“p53 dampens this cellular rewiring by inhibiting glycolysis through repression of genes such as the Glut1 and Glut4 glucose transporters and by promoting mitochondrial oxidative phosphorylation via activation of genes such as Sco2 [22].”
BackgroundInfluentialNeat1 is a p53-inducible lincRNA essential for transformation suppression
Mello, S. S., Sinow, C., Raj, N., Mazur, P. K., Bieging-Rolett, K., Broz, D. K., Imam, J. F. C., Vogel, H., Wood, L. D., Sage, J., et al. (2017) · Genes & Development · doi:10.1101/gad.284661.116 · Cited by 202
“In addition, p53 also regulates other processes, including autophagy and metabolic homeostasis, which may contribute to tumor suppression (Vousden and Prives 2009; Kenzelmann Broz et al. 2013; Kruiswijk et al. 2015).”
Kim, J., Yu, L., Chen, W., Xu, Y., Wu, M., Todorova, D., Tang, Q., Feng, B., Jiang, L., He, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.012 · Cited by 202
Apoptosis in Cancer Biology and Therapy
Moyer, A., Tanaka, K., & Cheng, E. H. (2025) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 173
Goetzman, E. S., & Prochownik, E. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00129 · Cited by 199
“In some cases, these losses not only delay or inhibit the apoptotic response to nutrient deprivation or the reactive oxygen species (ROS) associated with them but can themselves further alter metabolic pathways in favor of survival (18, 19).”
BackgroundThe role of NF-κB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy
Pavitra, E., Kancharla, J., Gupta, V. K., Prasad, K., Sung, J. Y., Kim, J., Tej, M. B., Choi, R., Lee, J.-H., Han, Y.-K., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114822 · Cited by 183
Senescent cells: a therapeutic target for cardiovascular disease
Childs, B. G., Li, H., & van Deursen, J. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95146 · Cited by 192
“Inhibition of BCL-family members using navitoclax (ABT-263) licenses BAX and BAD assembly at the mitochondrial outer membrane, forming the mitochondrial transmembrane pore and releasing cytochrome c to trigger the apoptotic caspase cascade (163).”
BackgroundSTAT6 inhibits ferroptosis and alleviates acute lung injury via regulating P53/SLC7A11 pathway
Yang, Y., Ma, Y., Li, Q., Ling, Y., Zhou, Y., Chu, K., Xue, L., & Tao, S. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04971-x · Cited by 185
“However, under high oxidative stress, the induction of P53 promotes ferroptosis, which always causes the tissue injury [60, 61].”
BackgroundMolecular and cellular pathways contributing to brain aging
Zia, A., Pourbagher-Shahri, A. M., Farkhondeh, T., & Samarghandian, S. (2021) · Behavioral and Brain Functions · doi:10.1186/s12993-021-00179-9 · Cited by 181
Preventing and Treating Anthracycline Cardiotoxicity: New Insights
Sawicki, K. T., Sala, V., Prever, L., Hirsch, E., Ardehali, H., & Ghigo, A. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030620-104842 · Cited by 177
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 177
Metabolic Plasticity in Chemotherapy Resistance
Desbats, M. A., Giacomini, I., Prayer-Galetti, T., & Montopoli, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00281 · Cited by 183
Redox Potential of Antioxidants in Cancer Progression and Prevention
George, S., & Abrahamse, H. (2020) · Antioxidants · doi:10.3390/antiox9111156 · Cited by 178
The Pentose Phosphate Pathway as a Potential Target for Cancer Therapy
Cho, E. S., Cha, Y. H., Kim, H. S., Kim, N. H., & Yook, J. I. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.179 · Cited by 178
“While the role of TIGAR in PPP flux is clear, it should be noted that p53 is involved in various levels of metabolic PPP circuitry other than TIGAR (for the effect of p53 on metabolism, see Kruiswijk et al., 2015).”
DNA damage and oxidant stress activate p53 through differential upstream signaling pathways
Shi, T., van Soest, D. M. K., Polderman, P. E., Burgering, B. M. T., & Dansen, T. B. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.06.013 · Cited by 172
Regulated cell death and adaptive stress responses
Galluzzi, L., Bravo-San Pedro, J. M., Kepp, O., & Kroemer, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2209-y · Cited by 177
“If DNA can be fully repaired, the activation state and expression levels of all these proteins return to baseline conditions, and the adaptive response to stress is shut down [25].”
BackgroundKietzmann, T., Mennerich, D., & Dimova, E. Y. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00011 · Cited by 176
“The murine double minute-2 (mdm2) and its human ortholog HDM2 protein are negative regulators of the p53 tumor suppressor protein (for review see Eischen and Lozano, 2009; Kruiswijk et al., 2015).”
BackgroundFerroptosis in Cancer Treatment: Another Way to Rome
Wu, Y., Yu, C., Luo, M., Cen, C., Qiu, J., Zhang, S., & Hu, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.571127 · Cited by 174
Metadata
- Authors
- Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H.
- Affiliations
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Vousden, Karen H.
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2015-06-23
- Volume
- 16
- Issue
- 7
- Pages
- 393-405
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W1890766043
- Cited by
- 1,080
- References
- 177
- Citations by year
- 2026: 37 · 2025: 54 · 2024: 67 · 2023: 119 · 2022: 133 · 2021: 148 · 2020: 108 · 2019: 104 · 2018: 110 · 2017: 101 · 2016: 84 · 2015: 15
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Cancer Research UK (C596/A10419, 18274)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- p53, tumour suppressor, cell survival, cell death, glycolysis, oxidative phosphorylation, reactive oxygen species, cancer metabolism, tumor progression
- MeSH terms
- Animals, Cell Survival, Humans, Tumor Suppressor Protein p53, Cell Death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.